- Argonaut has secured a $45M investment to expand its aseptic fill/finish capabilities. This facility will have a special filling line, isolated from the rest and this new setup will increase the current fill/finish capacity by more than four times.
Argonaut Manufacturing Services, a full-service contract development and manufacturing organisation, has announced $45 million in funding. This money is going to be used to increase their drug product fill/finish operations in Carlsbad, California.
They’ve been working on this expansion since early 2023. As part of this expansion, they’re building a new facility. This facility will have a top-notch isolator-based filling line. This new line will allow them to do more than four times the amount of drug product fill/finish work they currently do. It will also improve their ability to fill vials for pre-filled syringes and cartridges. These will be used for clinical and commercial supply. By 2025, Argonaut expects to have fully checked and approved the facility and all its equipment.
Wayne Woodard, founder and CEO of Argonaut, said, “Argonaut is uniquely positioned to address the manufacturing challenges that biopharma innovators face related to sterile fill / finish of complex and high-value drug products. We remain laser focused on leveraging our experienced team’s commitment to flexibility and client satisfaction while prioritizing quality and compliance. The recent commitment from NewVale Capital and the continued support of Telegraph Hill Partners paves a straight path to capacity expansion and fulfillment of our mission to become the world’s best Drug Product Manufacturing solutions provider for our clients.”
Stay ahead of trends and best practices
